AMLX icon

Amylyx Pharmaceuticals

Positive
Neutral
Negative
Sentiment 3-Months
Positive
Neutral 92.3%
Negative

Neutral
PRNewsWire
9 days ago
Kuehn Law Encourages Investors of Amylyx Pharmaceuticals, Inc. to Contact Law Firm
NEW YORK , Oct. 6, 2025 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX)  breached their fiduciary duties to shareholders.  According to a federal securities lawsuit, Amylyx insiders caused the company to misrepresent or fail to disclose that (i) RELYVRIO's commercial prospects were overstated; (ii) patients were discontinuing treatment with RELYVRIO after six months; (iii) the rate at which new patients were starting treatment with RELYVRIO was decreasing; (iv) accordingly, RELYVRIO's prescription rate was also overstated; (v) insiders attempted to hide the foregoing negative trends from investors and the market by blocking analysts from viewing RELYVRIO's prescription data; and (vi) as a result, the Company's public statements were materially false and misleading at all relevant times.
Kuehn Law Encourages Investors of Amylyx Pharmaceuticals, Inc. to Contact Law Firm
Neutral
Business Wire
1 month ago
Amylyx Pharmaceuticals Announces Pricing of $175 Million Underwritten Public Offering of Common Stock
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced the pricing of an underwritten public offering of 17,500,000 shares of its common stock at a public offering price of $10.00 per share. All of the shares of common stock are being offered by Amylyx. In addition, Amylyx has granted the underwriters a 30-day option to purchase up to an additional 2,625,000 shares of its common stock at the public offering price per share, les.
Amylyx Pharmaceuticals Announces Pricing of $175 Million Underwritten Public Offering of Common Stock
Neutral
Business Wire
1 month ago
Amylyx Pharmaceuticals Announces Proposed Public Offering of Common Stock
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals Announces Proposed Public Offering of Common Stock.
Amylyx Pharmaceuticals Announces Proposed Public Offering of Common Stock
Neutral
Seeking Alpha
1 month ago
Amylyx Pharmaceuticals, Inc. (AMLX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX ) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 4:50 PM EDT Company Participants Justin Klee - Co-Founder, Co-CEO & Director Joshua Cohen - Co-Founder, Co-CEO & Director Presentation Unknown Analyst Good afternoon. I'm just going to read this disclosure.
Amylyx Pharmaceuticals, Inc. (AMLX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Neutral
Seeking Alpha
1 month ago
Amylyx Pharmaceuticals, Inc. (AMLX) Presents At Citi's Biopharma Back To School Conference Transcript
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX ) Citi's Biopharma Back to School Conference September 2, 2025 1:00 PM EDT Company Participants Joshua Cohen - Co-Founder, Co-CEO & Director Justin Klee - Co-Founder, Co-CEO & Director Presentation Unknown Analyst [Audio Gap] Question-and-Answer Session Joshua Cohen Co-Founder, Co-CEO & Director [Audio Gap] asset. It's a GLP-1 receptor antagonist.
Amylyx Pharmaceuticals, Inc. (AMLX) Presents At Citi's Biopharma Back To School Conference Transcript
Negative
Reuters
1 month ago
Amylyx to stop development of rare brain disorder drug after trial failure
Amylyx Pharmaceuticals said on Wednesday it will discontinue development of its experimental drug for a rare brain disorder after the treatment failed to show benefit in a mid-stage trial.
Amylyx to stop development of rare brain disorder drug after trial failure
Neutral
Business Wire
1 month ago
Amylyx Pharmaceuticals to Discontinue ORION Program of AMX0035 for Progressive Supranuclear Palsy (PSP)
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals to Discontinue ORION Program of AMX0035 for Progressive Supranuclear Palsy (PSP).
Amylyx Pharmaceuticals to Discontinue ORION Program of AMX0035 for Progressive Supranuclear Palsy (PSP)
Neutral
Business Wire
1 month ago
Amylyx Pharmaceuticals to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals to Participate in Upcoming Investor Conferences.
Amylyx Pharmaceuticals to Participate in Upcoming Investor Conferences
Neutral
Seeking Alpha
2 months ago
Amylyx Pharmaceuticals, Inc. (AMLX) Q2 2025 Earnings Call Transcript
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX ) Q2 2025 Earnings Conference Call August 7, 2025 8:00 AM ET Company Participants Camille L. Bedrosian - Chief Medical Officer James M.
Amylyx Pharmaceuticals, Inc. (AMLX) Q2 2025 Earnings Call Transcript
Neutral
The Motley Fool
2 months ago
Amylyx (AMLX) Q2 Net Loss Narrows 43%
Amylyx (AMLX) Q2 Net Loss Narrows 43%
Amylyx (AMLX) Q2 Net Loss Narrows 43%